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Abstract
Objective To obtain summary estimates of the accuracy of a single
baseline measurement of the Elecsys Troponin T high-sensitive assay
(Roche Diagnostics) for the diagnosis of acute myocardial infarction in
patients presenting to the emergency department.
Design Systematic review andmeta-analysis of diagnostic test accuracy
studies.
Data sourcesMedline, Embase, and other relevant electronic databases
were searched for papers published between January 2006 and
December 2013.
Study selection Studies were included if they evaluated the diagnostic
accuracy of a single baseline measurement of Elecsys Troponin T
high-sensitive assay for the diagnosis of acute myocardial infarction in
patients presenting to the emergency department with suspected acute
coronary syndrome.
Study appraisal and data synthesis The first author screened all titles
and abstracts identified through the searches and selected all potentially
relevant papers. The screening of the full texts, the data extraction, and
the methodological quality assessment, using the adapted QUADAS-2
tool, were conducted independently by two reviewers with disagreements
being resolved through discussion or arbitration. If appropriate,
meta-analysis was conducted using the hierarchical bivariate model.
Results Twenty three studies reported the performance of the evaluated
assay at presentation. The results for 14 ng/L and 3-5 ng/L cut-off values
were pooled separately. At 14 ng/L (20 papers), the summary sensitivity
was 89.5% (95% confidence interval 86.3% to 92.1%) and the summary
specificity was 77.1% (68.7% to 83.7%). At 3-5 ng/L (six papers), the
summary sensitivity was 97.4% (94.9% to 98.7%) and the summary
specificity was 42.4% (31.2% to 54.5%). This means that if 21 of 100
consecutive patients have the target condition (21%, the median
prevalence across the studies), 2 (95% confidence interval 2 to 3) of 21
patients with acute myocardial infarction will be missed (false negatives)
if 14 ng/L is used as a cut-off value and 18 (13 to 25) of 79 patients
without acute myocardial infarction will test positive (false positives). If
the 3-5 ng/L cut-off value is used, <1 (0 to 1) patient with acute
myocardial infarction will be missed and 46 (36 to 54) patients without
acute myocardial infarction will test positive.
Conclusions The results indicate that a single baseline measurement
of the Elecsys Troponin T high-sensitive assay could be used to rule out
acute myocardial infarction if lower cut-off values such as 3 ng/L or 5
ng/L are used. However, this method should be part of a comprehensive
triage strategy and may not be appropriate for patients who present less
than three hours after symptom onset. Care must also be exercised
because of the higher imprecision of the evaluated assay and the greater
effect of lot-to-lot reagent variation at low troponin concentrations.
Systematic review registration PROSPERO registration number
CRD42013003926.
Introduction
Emergency physicians commonly encounter chest pain and
other symptoms suggestive of acute coronary syndrome, which
account for approximately 5% to 10% of all visits to the
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emergency department.1 2 Timely diagnosis of such patients,
especially ruling in or out of acute myocardial infarction, is of
paramount importance. Delays in confirming the diagnosis may
increase the risk of complications, and missing it may have fatal
consequences for the patient.3 4 Until recently, the triage tools
used by emergency physicians—clinical symptoms, history, 12
lead electrocardiogram, and standard troponin assays—did not
allow early exclusion of evolving acute myocardial infarction.
To avoid inadvertent discharge home, approximately 80% of
all patients with chest pain were admitted to hospital for clinical
observation and further testing, despite the fact that only a small
proportion of them (approximately 25%) were eventually
diagnosed as having myocardial infarction.5
The need to triage patients with chest pain more effectively and
efficiently—to avoid unnecessary hospital admissions and to
speed up the diagnostic process—has driven the development
of the so called high sensitivity cardiac troponin assays. To be
classified as high sensitivity, a cardiac troponin assay should
meet two criteria: firstly, its total imprecision (coefficient of
variation) at the 99th centile of the healthy reference population
should be 10% or less; secondly, measureable concentrations
above the limit of detection and below the 99th centile should
be attainable for at least 50% of the reference population.6Over
the past few years in the United Kingdom, standard troponin
assays have gradually been replaced with high sensitivity ones.
Although authoritative data on how and to what extent they are
used in different National Health Service trusts are unavailable,
anecdotal evidence strongly suggests both that standard troponin
assay use remains common and that where used high sensitivity
assays are being used in the same manner as standard troponin
assays, not capitalising on their greater sensitivity.
To improve this situation, the National Institute for Health and
Care Excellence (NICE) has recently published guidance on the
clinical application of high sensitivity troponin assays in the
early rule-out of acute myocardial infarction. The guidance
recommends the Elecsys Troponin T high-sensitive assay (Roche
Diagnostics) and the ARCHITECTSTAT high sensitive troponin
I (Abbott Laboratories) for use with early rule-out protocols
that include blood samples taken at the patient’s presentation
to the emergency department and a second sample three hours
later. A third assay, the AccuTnI+3 (Beckman Coulter) has also
been evaluated, but owing to insufficient evidence it is
recommended only for use in clinical research.7 The guidance
recommends the use of the 99th centile as a cut-off value when
deciding whether to rule out acute myocardial infarction or to
refer the patient for further investigations. Given the high
negative predictive value of high sensitivity troponin assays
and the fact that patients who present with very low cardiac
troponin concentrations also have a very low risk of myocardial
infarction, a rule-out strategy based on a single sample at
presentation and lower decision thresholds, such as the assay’s
limit of detection or limit of blank, has also been proposed.5
The limit of blank is the highest apparent analyte concentration
(analytical noise) expected to be found when replicates of a
blank sample containing no analyte are tested. The limit of
detection, on the other hand, is the lowest analyte concentration
likely to be reliably distinguished from the limit of blank and
at which detection is feasible.8 Using these cut-off values may
provide the means to identify patients at very low risk in whom
acute myocardial infarction could be excluded without a second
troponin measurement. The effectiveness and feasibility of such
a strategy, however, will depend on a range of factors, including
the diagnostic sensitivity and the precision of the assay at such
low threshold values.
We did a systematic review and meta-analyses of studies
evaluating the diagnostic accuracy of the Elecsys Troponin T
high-sensitive assay (hereinafter referred to as the high
sensitivity troponin T assay) for early diagnosis of acute
myocardial infarction in patients presenting to the emergency
department with chest pain and other symptoms suggestive of
acute coronary syndrome. The review protocol was registered
on the PROSPERO database (registration number
CRD42013003926). Here we report the results pertaining to the
hypothesis that a single use of the high sensitivity troponin T
assay at presentation is sensitive enough to allow the safe
exclusion of acute myocardial infarction. The accuracy estimates
obtained for serial measurements and change in troponin
concentration (the other objective stated in our review protocol)
will be reported in a separate publication.
The high sensitivity troponin T assay is a modification of
Roche’s fourth generation standard troponin T assay. The
specifications provided by the manufacturer are as follows. The
assay’s limit of blank is 3 ng/L, the limit of detection is 5 ng/L,
and the limit of quantification (the lowest analyte concentration
that can be reproducibly measured with coefficient of variation
of 10% or less) is 13 ng/L. The 99th centile of a healthy
reference population recommended as a positivity threshold for
the diagnosis of acute myocardial infarction is 14 ng/L, and the
estimated turnaround time is 18 minutes. The assay is also
available as a short turnaround time version with an estimated
turnaround time of nine minutes.9 It is commercially available
and in clinical use worldwide with the exception of the United
States, where it is used for research but has not yet obtained
clearance from the US Food and Drug Administration.6
Methods
We followed the recommendations of the Cochrane
Collaboration’s Diagnostic Test AccuracyGroup.10We searched
the following databases: OvidMedline andMedline in-process,
Ovid Embase, Science Citation Index, Medion database,
Database of Abstracts of Reviews of Effects (DARE), Cochrane
Database of Systematic Reviews (CDSR), Research Portfolio
Online Reporting Tools (RePORT, formally CRISP), and
International Network of Agencies for Health Technology
Assessment (INAHTA). The search strategies for Embase and
Medline are provided in web appendix 1. The initial validation
study of the high sensitivity troponin T assay was reported in
2010.11 To capture earlier studies using the pre-commercial
version of the assay, we extended the search period back to
January 2006 and hand searched the reference lists of all relevant
publications including systematic reviews and relevant opinion
papers.
The first author (ZZ) did the initial selection on the basis of
titles and abstracts. Full text copies of potentially relevant
publications were obtained and screened independently by two
reviewers (ZZ, HC, TJH), with all discrepancies resolved
through discussion or arbitration by a third reviewer (CH). We
used the reference management software EndNote X7 for the
selection process.We selected studies for inclusion in the review
if theymet the following pre-specified criteria: diagnostic cohort
studies, evaluating the diagnostic accuracy of the Roche high
sensitivity troponin T assay for the diagnosis of acute myocardial
infarction, in patients presenting to the emergency department
with suspected acute coronary syndrome, against a reference
standard based on the contemporary universal definition of acute
myocardial infarction,12 and published in peer reviewed journals.
We included in the meta-analyses reported here only those
studies reporting the diagnostic accuracy of the high sensitivity
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troponin T assay at the patient’s presentation to the emergency
department and using pre-specified positivity thresholds. Two
reviewers (ZZ, EY) used a standardised data extraction form to
independently abstract relevant details on the publication, the
study methods, and the results. We included publications
reporting results from the same study or studies based on
overlapping samples only if they complemented each other in
terms of reported results (for instance, if they reported results
for different cut-off values); we took care to avoid double
counting. We excluded studies if they failed to meet the
inclusion criteria or essential information was missing and could
not be obtained from the authors.
Two reviewers (ZZ, EY) independently assessed the
methodological quality of the included studies by using a
modified version of the QUADAS-2 tool (web appendix 2).13
Any disagreements were resolved through discussion and, if
necessary, arbitration by another reviewer (CH).
We constructed two-by-two tables, calculated sensitivity and
specificity with 95% confidence intervals, and created coupled
forest plots for each subset of data. We used random effects
bivariate models to do separate meta-analyses for different
pre-specified cut-off values.14We explored heterogeneity in the
first instance through visual examination of the forest plot and
the receiver operating characteristics plot for each set of raw
data.We considered the following sources of heterogeneity and,
if appropriate, added them to a bivariate regressionmodel: target
condition, reference test, patients’ characteristics, and
QUADAS-2 items. We did sensitivity analysis to check the
robustness of the results. We used Cook’s distance to identify
particularly influential studies and created a scatter plot of the
standardised predicted random effects (standardised level 2
residuals) to check for outliers.15 Then we refitted the model
leaving out any outliers and very influential studies, one at a
time, to check the robustness of the results. As standard funnel
plots and tests for publication bias are not recommended in
meta-analysis of diagnostic accuracy studies, we did not
investigate publication bias.10All data processing and statistical
analyses were done using Review Manager 5.2 and STATA
version 13 including the user written commands metandi and
midas.13 15-17
Results
The electronic searches identified 3071 records, of which 141
full text articles were assessed for eligibility. Thirty nine of
them met the criteria for inclusion in the review, and one
additional paper was included from the hand search.5 18-56Twenty
studies (23 papers) were included in the meta-analyses reported
here (fig 1⇓).5 19-23 28-32 34-37 39 41 42 45 53-56 Table 1⇓ shows their main
characteristics, and additional details are provided in
supplementary tables A-C.
Two of the 23 included papers reported results from the ongoing
multicentre study Advantageous Predictors of Acute Coronary
Syndromes Evaluation (APACE),35 53 and four reported results
from two other studies.19-22 The total number of patients in the
included studies was 9428, ranging from 13728 to 207235 53
(median 350, interquartile range 221-491). The reported mean
or median age of the included patients ranged from 5429 to 71
years41 (with the exception of the study by Bahrmann et al,23
which included only patients aged 70 years or over), and the
proportion of men ranged from 49%23 to 83%.39 One study
included only patients with coronary artery disease,39 and another
included unselected patients aged 70 or over presenting to the
emergency department with a non-surgical condition.23 Ten
studies defined specific time from onset of symptoms to
presentation as an inclusion criterion, which ranged from four
hours39 to 24 hours.5 Most of the patients presented to the
emergency department within 12 hours of symptom onset, with
study medians ranging from 3.5 hours5 to 6.3 hours,21 22 but the
average time was reported inconsistently. In 11 papers, the
results for non-ST elevationmyocardial infarction were reported
separately or patients with ST elevation on the initial
electrocardiogram were excluded from the study. The median
prevalence of acute myocardial infarction was 21.4%
(interquartile range 13.3-34.7%) and ranged from 8.0%29 to
56.2%.42
All included studies used a composite reference standard based
on the contemporary universal definition of myocardial
infarction.12 In terms of reference assays used to diagnose
myocardial necrosis, eight studies used serial high sensitivity
troponin T assay; 13 studies used standard troponin T or I assays,
or a combination of them; one study used a combination of
either standard troponin T or I (local assays) and high sensitivity
troponin I assays (central laboratory)29; one study used a
combination of standard and high sensitivity troponin T assays41;
and the reference assay in one study was unclear36 (in some
studies the accuracies according to different reference assays
were reported separately).
Twenty studies reported the performance of high sensitivity
troponin T at the manufacturer’s recommended cut-off value
of 14 ng/L, which represents the 99th centile of a healthy
reference population5 20 21 23 28-32 34-37 39 41 42 45 54-56; four studies
reported the performance of the test at 3 ng/L (limit of
blank)5 22 28 43 and four at 5 ng/L (limit of detection)19 22 34 53;
results for receiver operating characteristics optimised or other
cut-off values were also reported in some papers (table 1⇓ and
supplementary table C).
Table 2⇓ and supplementary table D show the results from the
assessment of themethodological quality of the included studies.
In approximately half of the studies, patients with ST elevation
myocardial infarction were not excluded. As cardiac markers
play no role in the diagnosis of this condition, which is made
primarily on the results from the electrocardiogram, including
patients with this diagnosis may compromise the applicability
of the results.32 The use of high sensitivity troponin T as part of
the reference standard may lead to incorporation bias, thus
inflating the accuracy estimates, whereas using a standard
troponin assay as a reference test may result in patients with
minor myocardial infarctions being misclassified as false
positives. We investigated the effect of using different
generations of reference assays in the meta-regression.
To obtain clinically relevant estimates of the performance of a
single baseline measurement of the high sensitivity troponin T
assay, we conducted, as far as the data permitted, separate
meta-analyses for the different pre-specified cut-off values
reported in the papers. The results from these meta-analyses are
presented below.
Performance of assay at 14 ng/L cut-off value
We pooled the results from 20 studies to obtain summary
estimates of the sensitivity and specificity at the 14 ng/L cut-off
value. When a study reported separately the results for non-ST
elevation myocardial infarction and acute myocardial infarction
(that is, both patients with ST and non-ST elevation myocardial
infarction were included in the study cohort), we included only
those for non-ST elevation myocardial infarction, which are
clinically more relevant. In a similar way, when both standard
troponin and high sensitivity troponin assays were used as
reference tests, we included only the results obtained with high
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sensitivity assays because, being more sensitive, they are able
to identify patients with small myocardial infarctions that would
bemissed by the standard assays. The target condition was acute
myocardial infarction in 10 studies and non-ST elevation
myocardial infarction in the remaining 10 studies; the reference
test was a standard troponin assay in nine studies, high
sensitivity troponin assay in eight, either standard or high
sensitivity in one, both standard and high sensitivity in one, and
unclear in one study. Figure 2⇓ shows a forest plot of the
coupled sensitivity and specificity with 95% confidence intervals
for each study included in this meta-analysis.
Pooling the results produced the following summary estimates:
sensitivity 89.5% (95% confidence interval 86.3% to 92.1%),
specificity 77.1% (68.7% to 83.7%), positive likelihood ratio
3.9 (2.8 to 5.4), and negative likelihood ratio 0.14 (0.10 to 0.18).
The summary receiver operating characteristics plot (fig 3⇓)
shows the summary sensitivity and specificity (the solid blue
spot in the middle) and the 95% confidence and prediction
regions (the inner and outer ellipses, respectively).
As shown in figures 2⇓ and 3⇓, a significant level of
heterogeneity was apparent in the results, greater in specificity
than in sensitivity. We investigated the effect of the target
condition (acute myocardial infarction versus non-ST elevation
myocardial infarction) and the reference test (standard versus
high sensitivity troponin assay) on the summary estimates of
sensitivity and specificity by adding them as covariates to a
bivariate regression model (one covariate at a time) and used a
likelihood ratio test to determine the statistical significance of
the results. As in two studies a combination of standard and
high sensitivity assays were used as a reference test,29 41 and the
type of the reference assay was unclear in another study,36 we
excluded those three studies from the meta-regression.Without
them, the likelihood ratio test showed that the use of different
reference standards accounts for some of the variability in the
sensitivity (P=0.008) but not in the specificity (P=0.66) (fig 4⇓).
A model that allowed for sensitivity and its variance to vary
between studies using different reference tests (standard versus
high sensitivity assays) produced the following summary
estimates: sensitivity (standard reference assay) 87.7% (82.6%
to 89.9%), sensitivity (high sensitivity reference assay) 93.4%
(89.8% to 95.7%), specificity 74.7% (73.6% to 75.8%), positive
likelihood ratio (standard reference assay) 3.43 (3.08 to 3.82),
positive likelihood ratio (high sensitivity reference assay) 3.69
(3.13 to 4.36), negative likelihood ratio (standard reference
assay) 0.18 (0.14 to 0.23), negative likelihood ratio (high
sensitivity reference assay) 0.09 (0.06 to 0.14). The target
condition, on the other hand, had no effect on the results
(P=0.79).
On the basis of the Cook’s distance, we found the following
studies to be the most influential in the meta-analysis (in
descending order): Khan et al,39 Melki et al,42 Invernizzi et al,37
and Collinson et al29 (fig 5⇓). Of these, only Khan et al was
identified as an outlier having the highest standardised residuals
for specificity (fig 6⇓). After refitting the model and leaving
this study out, we observed no change in sensitivity (89.5% v
89.7%) but specificity decreased from 77.1% to 74.9%. This
could be explained by the fact that this study excluded patients
without coronary artery disease, thus reducing the probability
of false positive results.
Performance of assaywhen either 3 ng/L (limit
of blank) or 5 ng/L (limit of detection) was
used as cut-off value
Seven papers reported the results for 3 ng/L and/or 5 ng/L
cut-off values at presentation.5 19 22 28 34 43 53 Given the small
number of studies, pooling the data for each cut-off value
separately would have produced unreliable results. Instead, we
decided to obtain more precise and reliable summary estimates
by including in the meta-analysis all independent 3 ng/L and 5
ng/L data.5 19 22 28 34 53 Two studies reported the results for both
cut-off values.22 43 53 As in this analysis we were interested
mainly in the sensitivity of the test (its accuracy for ruling out
acute myocardial infarction), we decided to include the results
for 5 ng/L as the performance at a higher cut-off value would
produce a lower sensitivity estimate thus representing the worse
case scenario. Owing to the inverse correlation between
sensitivity and specificity, we could assume that using even
lower cut-off values would further increase the sensitivity of
the assay and its ability to rule out the target condition. Thus,
from the APACE trial we excluded the results reported by
Meune et al,43 included those reported by Rubini Gimenez et
al,53 and included only the 5 ng/L data reported by Aldous et
al.22 Also, Christ et al reported two different sets of 3 ng/L
results, obtained using standard troponin T and high sensitivity
troponin T as refrence assays.28 As in the previous analysis, we
included the results obtained by using high sensitivity troponin
T as a reference assay, which is more sensitive and, thefeore,
more likely to capture small myocardial infarctions. Figure 7⇓
shows a forest plot of the sensitivities and specificities of the
included studies. Pooling the results from the six studies
produced the following summary estimates: sensitivity 97.4%
(94.9% to 98.7%), specificity 42.4% (31.2% to 54.5%), positive
likelihood ratio 1.69 (1.40 to 2.05), and negative likelihood ratio
0.06 (0.04 to 0.10) (fig 8⇓).
Discussion
In the meta-analyses reported here, we included 20 studies (23
papers) evaluating the diagnostic accuracy of a single baseline
determination of the Elecsys Troponin T high-sensitive assay
at pre-specified cut-off values in patients presenting to the
emergency department with suspected acute coronary syndrome.
We pooled data separately for 14 ng/L and for the combined 3
and 5 ng/L cut-off values. At 14 ng/L, the 99th centile of a
healthy reference population as reported by the manufacturer,
the summary sensitivity and specificity were 89.5% (95%
confidence interval 86.3% to 92.1%) and 77.1% (68.7% to
83.7%). This means that if the pre-test probability is 21% (the
median prevalence of the target condition across the studies),
then 21 of 100 tested patients will have a final diagnosis of acute
myocardial infarction; of them, between 18 and 19 will test
positive (true positives) and two or three will test negative (false
negatives). Of the 79 without the target condition, between 54
and 66 will test negative (true negatives) and between 13 and
25 will test positive (false positives).
Pooling all independent data for 3 ng/L and 5 ng/L cut-off values
produced a summary sensitivity of 97.4% (94.9% to 98.7%)
and a summary specificity of 42.4% (31.2% to 54.5%). This
means that of 21 patients with acute myocardial infarction,
between 20 and 21 will test positive (true positives) and between
none and one will be missed (false negatives). Of the 79 without
the target condition, between 25 and 43 will test negative (true
negatives) and between 36 and 54 will test positive (false
positives). Given the presence of a clear threshold
effect—sensitivity increases at the expense of specificity when
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a lower threshold is used—we can anticipate that in patients
with high sensitivity troponin T concentrations below 3 ng/L
the sensitivity will be even higher and no patients with
myocardial infarction will be missed. On the other hand, using
lower cut-off values will inevitably result in more false positives.
Strengths and limitations of study
These results should be treated with caution. They apply only
to a specific assay, the Elecsys Troponin T high-sensitive assay
(Roche Diagnostics), and may not generalise to other high
sensitivity assays by other manufacturers. The sensitivity of a
baseline measurement depends on the time between symptom
onset and blood draw. Although we were unable to investigate
this here, the results reported in the primary studies indicate
that in patients who present within three hours of symptom onset
the probability of false negatives is higher and a second
measurement may be needed to avoid the inadvertent discharge
of patients with an evolving acute myocardial infarction.5 18 53
One unexpected result in our review was the effect of the
reference assay on the summary estimates. The meta-regression
at a 14 ng/L cut-off value showed that the sensitivity estimate
was higher when serial high sensitivity troponin assay was used
as a reference test and lower when the reference test was a
standard troponin assay. Using a high sensitivity rather than a
standard troponin assay as a reference test would normally result
in fewer false positives. This is because patients with borderline
troponin concentrations that fall below the positivity threshold
of the standard assay but above that of the high sensitivity one
would be reclassified from false positives to true positives.20
Although this would affect the specificity of the test, it would
have little effect on its sensitivity. It is entirely possible that the
higher sensitivity obtained by using high sensitivity assay as a
reference test is a result of incorporation bias rather than a
reflection of a real effect. If this is the case, it is unlikely to have
affected the summary estimates obtained for the 3-5 ng/L cut-off
value, as in this meta-analysis all but one study used a standard
assay as the reference test.
Wewere unable to investigate the effect of some characteristics
of patients that are known to affect the accuracy of high
sensitivity troponin assays, such as age and comorbidities, as
such analysis would have required data from individual
patients.10 Most of these factors, however, affect the specificity
of the test owing to the increased number of false positives in
older patients or patients with other cardiac or non-cardiac
conditions and, therefore, are of little relevance to the question
we tried to answer here—namely, whether the evaluated test
has high enough sensitivity to allow exclusion of acute
myocardial infarction with a single baseline measurement.
A further threat to the validity of our results, especially those
related to 3-5 ng/L cut-off values, comes from the downward
shift observed in the Elecsys Troponin T high-sensitive assay
at low concentrations of the measurement interval.57 The shift
has caused as much as 88% of the samples from healthy people
to be measured with values below the limit of blank rather than
the 50% or less in the initial evaluation study.58 59 Recently, the
manufacturer Roche Diagnostics has made adjustments to return
the assay to its original specifications.57 58 As a consequence,
great care would need to be taken with the way the test is carried
out in practice to ensure that the test’s accuracy at low thresholds
achieved in the research reviewed is maintained consistently in
the long term. This need for care is reinforced by the assay’s
total imprecision being much higher at the low end of the
measurement interval compared with the required coefficient
of variation 10% or less at the 99th centile.
With these provisos, the results from the meta-analyses suggest
that although single measurement of high sensitivity troponin
T at presentation may result in unacceptably high number of
patients with acute myocardial infarction being missed if the
99th centile (14 ng/L) is used as a cut-off value, lowering the
decision threshold to the limit of blank or limit of detection
could increase the negative predictive value of the assay to a
point at which no patients with the target condition will be
missed.
To appreciate the significance of this result, we need to know
what proportion of patients actually present with baseline
concentrations below the assay’s limit of blank and limit of
detection. Two of the included studies reported such data. In
the study by Body et al, 195 (27.7%) of the included 703 patients
had undetectable (<3 ng/L) high sensitivity troponin T
concentrations at presentation and none of them was diagnosed
as having myocardial infarction. Of the 296 (42.1%) patients
who had concentrations between 3 ng/L and 14 ng/L, 19 (6.4%)
patients developed acute myocardial infarction.5 In the APACE
trial, as reported by Rubini Gimenez et al,53 of the 2245 patients
included in the analysis, 550 (25%) had values below 5 ng/L at
presentation and eight (1.5%) of themwere diagnosed as having
myocardial infarction. These studies show that a significant
proportion of the patients who undergo troponin testing in
emergency setting present with high sensitivity troponin T
concentrations below the limit of detection, and only a very
small proportion of them are later diagnosed as having acute
myocardial infarction. A diagnostic strategy that incorporates
a baseline measurement with the Elecsys Troponin T
high-sensitive assay and uses a low cut-off value, such as the
limit of blank or limit of detection, to rule out myocardial
infarction may help to reduce the number of patients who
undergo unnecessary further testing (often associated with
potentially harmful effects) and may save resources and relieve
pressure on overcrowded emergency departments. Patients with
troponin concentrations above this low rule-out threshold could
undergo the usual second sample testing before a decision about
discharge or admission for further investigations is made.
A recently published study by Body et al suggests that an
alternative to the low threshold rule-out strategy discussed above
might be available.60 In this study, the performance of the 99th
centile of the Elecsys Troponin T high-sensitive assay at
presentation was evaluated not as a standalone test but in
conjunction with the emergency physicians’ clinical judgment
(based on the patient’s history and clinical examination) and
the results from the initial electrocardiogram. When combined,
the diagnostic information from these three sources had 100%
(95.4% to 100%) sensitivity and 100% (95.7% to 100%)
negative predictive value. These findings suggest that the
summary estimates obtained from our meta-analyses may
underestimate the sensitivity of the assay and that using the 99th
centile cut-off value in a single measurement at presentation,
especially in patients who present more than three hours after
symptom onset, may be sufficient to rule out acute myocardial
infarction. As Body et al point out, however, such a strategy
needs to be prospectively validated in independent populations
before clinical implementation.
Comparison with other studies
As far as we are aware, the only other systematic review that
has investigated the performance of the Elecsys Troponin T
high-sensitive assay is the one by Westwood et al,61 which
underpins the National Institute for Health and Care Excellence’s
recent guidance on high sensitivity troponin assays.7 Our
findings are consistent with the NICE guidance to consider two
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of the high sensitivity troponin assays, including the one
evaluated in this study, as options for the early rule-out of
non-ST elevation myocardial infarction in people presenting to
an emergency department with chest pain and suspected acute
coronary syndrome. The NICE guidance was, however, more
cautious about using low cut-off values, expressing concern
about “the clinical and practical implications of introducing
limit of blank and limit of detection cut-off thresholds into
practice.”7
Conclusions and policy implications
In conclusion, when used with blood samples drawn at the
patient’s presentation to the emergency department and given
a pre-test probability of 21%, the Elecsys Troponin T
high-sensitive assay will miss two or three patients with acute
myocardial infarction if the 99th centile is used as a cut-off
value and no patients or one patient if 5 ng/L is used. Using 3
ng/L is likely to reduce even further the proportion of patients
with the target condition that would be missed. In patients
presenting within three hours of symptom onset, the proportion
of missed patients with acute myocardial infarction might be
higher. The above results suggest that if low cut-off values are
used a single measurement of high sensitivity troponin T at
presentation might be sufficient to rule out acute myocardial
infarction. Such a strategy would, however, need to be carefully
implemented owing to the high imprecision of the assay and
greater effect of lot-to-lot reagent variation at low troponin
concentrations. In clinical practice, the 99th centile of the index
assay used with samples taken at presentation might be able to
exclude acute myocardial infarction with sufficient accuracy
when combined with the results from the patient’s history,
clinical examination, and the initial electrocardiogram. This,
however, needs to be prospectively validated in independent
cohorts before implementation.
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Tables
Table 1| Characteristics of included studies
Median (IQR) time to
presentation
Sex (%
male)
Median (IQR)
or mean (SD)
age
Prevalence
of target
condition
(%)
Total No
included
Index test
cut-offs (ng/L)
Reference
assay
Target
condition
Study type and
locationPublication
4.0 (2.0-8.6) h60.264 (53-74)33.13325, 13, 14, 15
(ROC
optimised)
cTnIAMISingle centre, New
Zealand
Aldous 201119
6.3 (3.3-13.3) h59.765 (56-76)21.393914cTnINSTEMISingle centre, New
Zealand
Aldous 201121
4.0 (2.0-8.6) h60.264 (53-74)39.032214hs-cTnTAMISingle centre, New
Zealand
Aldous 201220
6.3 (3.3-13.3) h59.765 (56-76)21.89393, 5, 14, 17
(ROC
optimised)
cTnINSTEMISingle centre, New
Zealand
Aldous 201222
0-3 h: 79 (26%); 3-6
h: 42 (14%); 6-12 h:
25 (8%); >12 h: 161
(52%)
49.081 (6)12.430614hs-cTnTNSTEMISingle centre,
Germany
Bahrmann 201323
3.5 h61.259 (14)18.57035, 14cTnTAMISingle centre, UKBody 20115
Within 2 h: 36%; 2-6
h: 22%; 6-24 h: 33%;
>24 h: 20%
64.066 (16)15.0 (cTnT),
25.5
(hs-cTnT)
1373, 14cTnT,
hs-cTnT
AMISingle centre,
Germany
Christ 201028
8.25 (5.17-12.30) h60.054 (44-64)8.0483314cTnT, cTnI,
hs-cTnI
NSTEMIMulticentre, UKCollinson 201329
<4 h: 143 (39.7%)65.667 (58-76)35.636014cTnINSTEMIMulticentre, SwedenEggers 201230
NA65.057 (17)14.231714cTnIAMIMulticentre, FranceFreund 201131
0-3 h: 45.5%; 3-6 h:
19.5%; 6-12 h:
17.3%; >12 h: 15.1%;
missing data: 2.6%
63.063 (16)27.050314hs-cTnTAMISingle centre,
Germany
Giannitsis 201132
AMI: 2 (1-8) h; other
cardiac diseases: 3
(2-8) h; other
diseases: 3 (2-10) h
47.8 (all),
52.3 (chest
pain)
60 (21) (all
patients); 56
(20) (chest pain
patients only)
9.12384 (all),
440 (chest
pain)
5, 14, 20 (ROC
optimised), 30,
45 (optimised
for LR+ and
LR-
respectively)
cTnTAMISingle centre,
Austria
Hammerer-Lercher
201334
<3 h: 24.4%; ≥3 h:
75.6%
68.862 (50-75)21.4207214cTnT, cTnIAMIMulticentre
(APACE),
Switzerland, Italy,
Spain
Hoeller 201335
NA73.067 (59-75)35.920914UnclearNSTEMIMulticentre, JapanInoue 201136
NA58.068 (17)8.338614cTnTAMISingle centre, ItalyInvernizzi 201337
358 (152-929.3) min83.058 (10)33.918012, 14, 17hs-cTnTAMISingle centre,
Pakistan
Khan 201139
NA76.071 (14)9.214214cTnT,
hs-cTnT
AMISingle centre,
Germany
Lotze 201141
5.3 (3.3-7.5) h67.065 (55-76)56.223314cTnT, cTnI,
hs-cTnT
NSTEMISingle centre,
Sweden
Melki 201142
NA52.5 (≥75
years);
71.5 (<75
years)
81 (78-85) (in
patients ≥75
years); 66
(56-71) (in
patients <75
years)
48.234214, 27 (ROC
optimised)
hs-cTnTNSTEMISingle centre,
Germany
Normann 201245
<3 h: 24.4%; ≥3 h:
75.6%
68.862 (50-75)21.420725cTnT, cTnIAMIMulticentre
(APACE),
Switzerland, Italy,
Spain
Rubini Gimenez
201353
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Table 1 (continued)
Median (IQR) time to
presentation
Sex (%
male)
Median (IQR)
or mean (SD)
age
Prevalence
of target
condition
(%)
Total No
included
Index test
cut-offs (ng/L)
Reference
assay
Target
condition
Study type and
locationPublication
<3 h: 46.2%67.969 (27-93)22.135814; 12.2, 25
(ROC
optimised)
cTnTNSTEMIMulticentre, SpainSantaló 201354
NSTEMI: 3.65
(2.75-12) h; UA: 3.76
(2.32-6.50) h; AP:
2.82 (2.63-4.5) h;
NCAD: 5.32
(3.05-9.68)
63.461 (48-75)15.016714, 18 (ROC
optimised)
cTnINSTEMISingle centre,
France
Sebbane 201355
Unclear63.066 (55-76)14.647814hs-cTnTNSTEMISingle centre,
Sweden
Thelin 201356
AMI=acute myocardial infarction; AP=angina pectoris; cTnI=cardiac troponin I; cTnT=cardiac troponin T; hs=high sensitivity; IQR=interquartile range; LR=likelihood
ratio; NA=not available; NCAD=non-coronary artery disease; NSTEMI=non-ST segment myocardial infarction; ROC=receiver operating characteristics; UA=unstable
angina.
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Table 2| Methodological quality assessment of included studies
Time and flowReference standardIndex textPatient selection
Study Risk of bias
Concerns about
applicabilityRisk of bias
Concerns about
applicabilityRisk of bias
Concerns about
applicabilityRisk of bias
HighHighLowLowLowHighLowAldous 201119
LowHighHighLowLowHighLowAldous 201220
LowLowLowLowLowLowLowAldous 201221
LowLowLowLowLowLowHighAldous 201222
LowLowHighLowLowHighLowBahrmann 201323
LowHighLowLowLowHighUnclearBody 20115
LowHighHighLowLowHighLowChrist 201028
HighLowLowLowLowLowLowCollinson 201329
HighLowUnclearLowLowHighUnclearEggers 201230
LowHighLowLowLowHighLowFreund 201131
LowHighHighLowLowHighUnclearGiannitsis 201132
LowHighYesLowLowHighLowHammerer-Lercher 201334
LowHighLowLowLowHighLowHoeller 201335
LowLowUnclearLowLowLowUnclearInoue 201136
LowHighUnclearLowLowHighLowInvernizzi 201337
LowHighHighLowLowHighHighKhan 201139
LowHighHighLowLowHighLowLotze 201141
LowLowLowLowLowHighHighMelki 201142
LowLowHighLowLowLowLowNormann 201245
LowHighLowLowLowHighLowRubini Gimenez 201353
LowLowUnclearLowLowLowLowSantaló 201354
HighLowLowLowLowLowUnclearSebbane 201355
LowLowHighLowLowLowLowThelin 201356
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;350:h15 doi: 10.1136/bmj.h15 (Published 14 January 2015) Page 10 of 14
RESEARCH
Figures
Fig 1 Flow chart of selection process. hs-cTnT=high sensitivity cardiac troponin T; ROC=receiver operating characteristics
Fig 2 Forest plots of coupled sensitivity and specificity at 14 ng/L (99th centile). FN=false negative; FP=false positive;
TN=true negative; TP=true positive. See footnote to table 1⇓ for other abbreviations
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Fig 3 Summary receiver operating characteristics plot of sensitivity and specificity at 14 ng/L cut-off value. Each rectangle
represents an individual study; size of symbol reflects inverse standard error of specificity (width) and sensitivity (height)
estimates; solid spot in middle is summary sensitivity and specificity; inner ellipse represents 95% confidence region, and
outer ellipse represents 95% prediction region
Fig 4 Summary receiver operating characteristics plot comparing effect of different reference tests (standard troponin assay
v high sensitivity troponin assay) on summary estimates of sensitivity and specificity (Inoue 2011,36 Lotze 2011,41 and
Collinson 201329 were
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Fig 5 Influence analysis
Fig 6 Outlier detection
Fig 7 Forest plot of studies included in meta-analysis of combined 3 ng/L and 5 ng/L. FN=false negative; FP=false positive;
TN=true negative; TP=true positive. See footnote to table 1⇓ for other abbreviations
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Fig 8 Summary receiver operating characteristics plot of sensitivity and specificity for cut-off value of either 3 ng/L or 5 ng/L
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